Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -316.9%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $786M | $3.1B | $9.6B | $144M | $56M | $416M | $1.5B | $2.2B | — | — |
| Enterprise Value | $783M | $3.0B | $9.6B | $144M | $44M | $374M | $1.4B | $2.1B | — | — |
| P/E Ratio → | -0.01 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 397.17 | 46.65 | 2.65 | 8.75 | 25.60 | 25.95 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -316.9% | -316.9% | -130.2% | -217.0% | -82.6% | -69.0% | -42.4% | -32.3% | -46.8% | -55.8% |
| ROA | -63.8% | -63.8% | -51.9% | -74.2% | -45.8% | -48.8% | -37.0% | -29.9% | -42.9% | -46.0% |
| ROIC | -444.8% | -444.8% | -305.2% | -336.8% | -281.2% | -164.5% | -113.0% | -70.2% | -50.8% | — |
| ROCE | -66.6% | -66.6% | -159.9% | -107.6% | -52.1% | -54.5% | -40.6% | -34.3% | -46.7% | -58.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.40 | 4.90 | 0.92 | 0.42 | 0.10 | 0.01 | — | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.34 | 0.06 | -0.57 | -0.89 | -0.53 | -0.84 | -0.20 | -0.60 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -35.78 | -35.78 | -5.36 | -9.85 | -12.65 | -50.73 | -4322.57 | -346.98 | — | — |
Net cash position: cash ($5M) exceeds total debt ($1M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.87 | 0.87 | 2.48 | 1.58 | 4.65 | 6.03 | 8.47 | 13.58 | 24.34 | 5.81 |
| Quick Ratio | 0.87 | 0.87 | 2.48 | 1.58 | 4.65 | 6.03 | 8.47 | 13.58 | 24.35 | 5.81 |
| Cash Ratio | 0.78 | 0.78 | 2.15 | 1.33 | 4.20 | 5.62 | 7.87 | 13.24 | 24.20 | 5.58 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $1.6B | $691M | $3M | $2M | $1M | $1M | $1M | $1M | $1M |
Critical liquidity and dilution
As reported in financial statements, PHGE's ROIC has fluctuated wildly, reaching -54.1% in 2025Q3, which highlights the company's inability to generate positive returns on invested capital while it continues to consume resources to advance its clinical-stage phage therapy pipeline through high-cost development phases.
The extreme volatility in ROIC, including a transient positive spike in 2024Q4, appears to be driven by non-operating accounting adjustments rather than operational efficiency. Investors should interpret these negative returns as a reflection of the inherent difficulty in compounding capital within a pre-revenue biotech model that lacks a commercialized product.
According to recent SEC filings, the company's current ratio has compressed from 4.80 in 2024Q2 to 1.24 in 2026Q1, signaling a rapidly diminishing liquidity cushion that leaves the firm increasingly vulnerable to operational disruptions or the need for highly dilutive emergency financing to sustain its research activities.
The decline in the current ratio suggests that the company is struggling to maintain a sufficient working capital buffer to cover its near-term liabilities. This trend warrants close monitoring, as the lack of revenue generation means that the firm's survival is entirely contingent upon its ability to access external capital markets.
Based on the company's reported figures, the debt-to-equity ratio has shown significant instability, peaking at 4.90 in 2023Q4, which suggests that the firm's capital structure is highly sensitive to equity dilution and the periodic revaluation of its outstanding liabilities in a pre-revenue context.
The erratic nature of the debt-to-equity ratio reflects the company's reliance on non-traditional financing and the impact of accounting treatments on its balance sheet. Analysts should be cautious, as the reported leverage metrics may not accurately represent the firm's long-term solvency risk given the absence of recurring cash flows.
As indicated by the company's financial disclosures, the days payable outstanding (DPO) has fluctuated between 137 and 1007 days over the last ten quarters, reflecting the unpredictable timing of clinical trial-related payments and the firm's reliance on extended credit terms from its research partners.
The extreme variance in DPO suggests that the company may be managing its cash outflows by delaying payments to vendors, which is a common but unsustainable strategy for firms facing severe liquidity constraints. This behavior may indicate underlying pressure on the firm's ability to meet its contractual obligations in a timely manner.
The P/E ratio is frequently misapplied to PHGE, as the company's lack of commercial revenue and persistent net losses render earnings-based valuation metrics entirely meaningless for assessing the firm's intrinsic value or its potential for future clinical success in the phage therapy market.
Investors should instead focus on metrics such as cash-to-market-cap ratios or the probability-adjusted net present value of the clinical pipeline. Relying on traditional multiples in this context obscures the reality that the company is an option on future clinical data rather than a mature, earnings-generating business.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PHGE stock.
BiomX Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
BiomX Inc.'s return on equity (ROE) is -316.9%. The historical average is -110.3%.
Based on historical data, BiomX Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.